Puma Biotechnology Inc (NASDAQ:PBYI) Stake Lifted by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd grew its holdings in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 28.5% in the fourth quarter, HoldingsChannel reports. The fund owned 29,844 shares of the biopharmaceutical company’s stock after buying an additional 6,627 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Puma Biotechnology were worth $261,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the business. State Street Corp lifted its holdings in shares of Puma Biotechnology by 18.3% during the fourth quarter. State Street Corp now owns 3,507,152 shares of the biopharmaceutical company’s stock valued at $30,688,000 after purchasing an additional 541,496 shares during the last quarter. Acadian Asset Management LLC increased its position in Puma Biotechnology by 119.5% in the 4th quarter. Acadian Asset Management LLC now owns 839,122 shares of the biopharmaceutical company’s stock worth $7,344,000 after purchasing an additional 456,921 shares during the last quarter. Point72 Asset Management L.P. increased its position in Puma Biotechnology by 111.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 506,221 shares of the biopharmaceutical company’s stock worth $5,449,000 after purchasing an additional 267,048 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Puma Biotechnology by 49.3% during the 3rd quarter. Millennium Management LLC now owns 677,395 shares of the biopharmaceutical company’s stock valued at $7,292,000 after acquiring an additional 223,564 shares during the last quarter. Finally, Credit Suisse AG increased its holdings in shares of Puma Biotechnology by 617.9% during the 4th quarter. Credit Suisse AG now owns 135,997 shares of the biopharmaceutical company’s stock valued at $1,190,000 after acquiring an additional 117,052 shares during the last quarter. Institutional investors own 80.47% of the company’s stock.

PBYI stock opened at $9.25 on Thursday. The business’s 50-day moving average price is $10.68 and its two-hundred day moving average price is $9.30. The company has a current ratio of 1.83, a quick ratio of 1.80 and a debt-to-equity ratio of 6.73. Puma Biotechnology Inc has a 1-year low of $5.50 and a 1-year high of $39.88.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.19. The firm had revenue of $62.90 million for the quarter, compared to analyst estimates of $57.32 million. Puma Biotechnology had a negative return on equity of 302.75% and a negative net margin of 27.76%. As a group, analysts expect that Puma Biotechnology Inc will post -1.48 earnings per share for the current year.

PBYI has been the subject of several recent analyst reports. Royal Bank of Canada restated a “hold” rating and set a $13.00 target price on shares of Puma Biotechnology in a research note on Monday, January 27th. BidaskClub raised Puma Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Guggenheim cut Puma Biotechnology from a “buy” rating to a “neutral” rating in a report on Friday, January 3rd. SVB Leerink reissued a “market perform” rating on shares of Puma Biotechnology in a research note on Tuesday, February 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Puma Biotechnology in a research note on Wednesday, February 26th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company’s stock. Puma Biotechnology currently has a consensus rating of “Hold” and a consensus target price of $12.03.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).

Further Reading: Catch-Up Contributions

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.